299 related articles for article (PubMed ID: 36949948)
1. Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments.
Chen S; Tang J; Liu F; Li W; Yan T; Shangguan D; Yang N; Liao D
Front Immunol; 2023; 14():1094764. PubMed ID: 36949948
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
3. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
Lin A; Wei T; Meng H; Luo P; Zhang J
Mol Cancer; 2019 Sep; 18(1):139. PubMed ID: 31526368
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
5. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.
Fang Y; Wang Y; Zeng D; Zhi S; Shu T; Huang N; Zheng S; Wu J; Liu Y; Huang G; Xue Y; Bin J; Liao Y; Shi M; Liao W
Oncoimmunology; 2021; 10(1):1951019. PubMed ID: 34345533
[TBL] [Abstract][Full Text] [Related]
8. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
9. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy.
Singh SS; Dahal A; Shrestha L; Jois SD
Curr Med Chem; 2020; 27(32):5274-5316. PubMed ID: 30854949
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Takashima Y; Sakakibara-Konishi J; Hatanaka Y; Hatanaka KC; Ohhara Y; Oizumi S; Hida Y; Kaga K; Kinoshita I; Dosaka-Akita H; Matsuno Y; Nishimura M
Clin Lung Cancer; 2018 Jul; 19(4):352-359.e1. PubMed ID: 29544718
[TBL] [Abstract][Full Text] [Related]
12. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
14. Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.
Li D; Song Z; Dong B; Song W; Cheng C; Zhang Y; Zhang W
J Clin Pharm Ther; 2022 Jan; 47(1):24-32. PubMed ID: 34309914
[TBL] [Abstract][Full Text] [Related]
15. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
17. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
18. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for lung cancer: Beyond EGFR and ALK.
Herrera-Juárez M; Serrano-Gómez C; Bote-de-Cabo H; Paz-Ares L
Cancer; 2023 Jun; 129(12):1803-1820. PubMed ID: 37073562
[TBL] [Abstract][Full Text] [Related]
20. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
